Telix Pharmaceuticals Limited - Capital Markets Day - TELIX PHARMACEUTICALS LTD

Explicit Guidance:

• FY2026 revenue expected to reach approximately $1 billion USD, targeting the top end of the maintained guidance range.
• FY2027 revenue forecast to grow to approximately $1.5 billion USD (approx. $2 billion AUD), driven by the addition of ITM revenue, expanded product portfolio, and commercialization of new assets.
• Precision medicine business (imaging) expected to grow >25% year-over-year in FY2026 and sustain this trajectory.
• ITM business revenue is expected to grow at an 18% CAGR over the next five years, supported by long-term contracts extending into the 2030s.
• FY2028 targeted as the year the company transitions to an earnings growth story.
• Gross margins for the precision medicine business have been improved to 65% and are expected to expand further with therapeutic commercialization.
• ITM acquisition expected to generate approximately $50 million in synergies within the first two years post-closing.
• Annual capital expenditure of approximately $100 million to continue building and growing manufacturing infrastructure (cyclotrons, radiation capabilities) over the coming years.

Business-Segment Outlook:

• Product Portfolio Expansion: Number of FDA-approved products expected to increase from 3 to 6 by next year (2027).
  • PixClara (Fluciclovine): Revenue expected to double in the next 12 months; usage expanding to brain cancer (glioma) imaging in the coming months.
  • Bypass (Gallium-68 PSMA): Awaiting FDA resubmission; expected to potentially triple the volume of patients serviced via a distinct market access strategy.
  • Zircaix (Zirconium-89): FDA approval anticipated in 2027; expected to transform diagnosis/staging of clear cell renal cell carcinoma (CCRCC).
  • Lutetium-177-based Therapeutics (TLX597 & TLX591): Moving earlier in treatment paradigms (dose intensification/adaptation for early metastatic disease) and late-line settings; expected to drive significant margin lift upon approval.
  • Kidney Cancer (TLX250/Luteon): Phase 3 trial enrolling rapidly; aim to show overall survival benefit in late-line disease before moving upstream.
  • Brain Cancer (TLX101): IPAX-BRIGHT (Phase 3) and IPAXT2 (Phase 2) studies ongoing; potential to address a "20-year drug development desert" in glioblastoma.
• Geography: Commercially active in 22 countries; expansion planned in EMEA; committed to a "globally active" model to maximize partnership and revenue opportunities.
• Manufacturing: 45 global sites handling radioactivity; expanding infrastructure to include Actinium-222 production in Philadelphia (US) and Lutetium-177 in Europe (7 new GMP licenses).
• Revenue Mix: Shift anticipated from purely imaging-focused to a balanced therapeutics and imaging model by 2027-2028.

Market and Competitive Outlook:

• Market Growth: Radiopharmaceutical sector described as entering a "boom" (non-transactional growth) driven by therapeutics rather than just diagnostics.
• Therapeutics Transformation: Market growth over the next decade is expected to be driven almost exclusively by therapeutics, which will outpace diagnostic imaging growth.
• Supply Chain Dynamics: Industry race involves two parallel tracks: pipeline development and commercialization infrastructure. Telex views owning the supply chain as a critical differentiator to guarantee delivery and margin control.
• Competitive Advantage: Telex aims to be the "shop front" and strategic partner for the ~100 other drugs and 50+ companies in development that lack infrastructure to deliver isotopes globally.
• Pricing/Market Access: Strategy involves controlling dissemination and pricing dynamics through a vertical integration model, avoiding the disintermediation common in traditional nuclear medicine.

Macro / Industry Outlook:

• Regulatory Environment: Telex expects regulatory clarity (e.g., FDA interactions with Zircaix) to enhance their ability to navigate complex biologics and therapeutics pipelines.
• Clinical Paradigm Shift: Anticipated shift in prostate cancer diagnostics from post-treatment imaging to pre-biopsy imaging (driven by Bypass study results), potentially impacting biopsy rates and staging accuracy.
• Investment Landscape: Market is consolidating; the "wheat from chaff" separation expected in the next two years. Telex positions itself as a self-powered entity reducing the need for shareholder dilution compared to peers.
• Supply Scarcity: Limited global infrastructure (cyclotrons/reactors) creates a barrier to entry; Telex views this as a moat.

Strategic Initiatives:

• ITM11 Acquisition: Expected to close soon; integrates global isotope supply chain (80% of world's Lutetium) with Telex's pipeline. Targets 2027 as the commercial year for the combined therapeutic platform.
• Regeneron Collaboration: Focus on alpha-emitting isotopes (Actinium-225, Lead-212, Astatine); includes a dedicated facility in Philadelphia for alpha-trait development and clinical trial facilitation.
• Pipeline Synergies: Leveraging ITM's isotope portfolio (including Actinium and Lead) to accelerate development of Telex's alpha-therapy assets.
• Commercial Infrastructure: Continued investment in a distinct commercial organization (unusual for size) to manage complex clinical workflows and supply chains.

Risks and Headwinds to Outlook:

• Regulatory Delays: Past delays in Zircaix resubmission highlight potential timelines for biologics and complex therapeutics; FDA expectations are evolving.
• Supply Chain Complexity: Scaling production of isotopes (e.g., Actinium) and managing "last-mile" delivery requires significant capital and execution precision; any missed dose can damage clinical partner relationships.
• Clinical Trial Failure: Future growth relies on successful readouts of late-stage trials (Prostate Global, IPAX-BRIGHT, Luteon) and regulatory approvals.
• Competitive Intensity: High number of new entrants (50+ companies) competing for limited supply chain infrastructure and market share in therapeutics.
• Adoption Rates: Success of Bypass and CA9 imaging depends on reimbursement coverage and adoption by clinicians to shift diagnostic paradigms (e.g., pre-biopsy).

Management Tone on the Future:

• Confidence: Management expresses high confidence in the "multi-product, multi-jurisdictional" strategy and the "race to build infrastructure" as a competitive moat.
• Strategic Shift: Tone indicates a deliberate pivot from a "small biopharma" model to a "global radiopharma powerhouse" with integrated R&D, manufacturing, and commercialization.
• Forward-Looking: Emphasis on 2027-2028 as the inflection point for earnings growth and capital markets recognition.
• Risk Management: Acknowledges the "vicious cycle" of the past (need for isotopes to run trials, need for trials to justify isotopes) but views current position as breaking that cycle.